Jeffrey S Huo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2422166/publications.pdf

Version: 2024-02-01

430754 501076 33 936 18 28 citations h-index g-index papers 34 34 34 2179 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701. Transplantation and Cellular Therapy, 2022, 28, S130-S131.	0.6	0
2	Running the full human developmental clock in interspecies chimeras using alternative human stem cells with expanded embryonic potential. Npj Regenerative Medicine, 2021, 6, 25.	2.5	7
3	Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplantation, 2021, 56, 2997-3007.	1.3	4
4	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Advances, $2021, 5, 1-11$.	2.5	46
5	Vascular progenitors generated from tankyrase inhibitor-regulated na \tilde{A} -ve diabetic human iPSC potentiate efficient revascularization of ischemic retina. Nature Communications, 2020, 11, 1195.	5.8	16
6	BK polyomavirus nephropathy with systemic viral spread: Whole genome sequencing data from a fatal case of BKPyV infection. Transplant Infectious Disease, 2020, 22, e13269.	0.7	6
7	Incidence and Outcomes of Patients with Thrombotic Microangiopathy after Transplant: Results of Prospective Screening through a Multi-Institutional Collaborative. Biology of Blood and Marrow Transplantation, 2020, 26, S92.	2.0	3
8	Reduced Intensity Vs Myeloablative Conditioning Regimen for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, S14-S15.	2.0	О
9	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in the First Prospective Multicenter Trial for Pediatric, Adolescent, and Young Adult Patients with High Risk Acute Leukemias and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2019,	2.0	5
10	25,000. Tolerance and effectiveness of nivolumab after pediatric Tâ€cell replete, haploidentical, bone marrow transplantation: A case report. Pediatric Blood and Cancer, 2017, 64, e26257.	0.8	22
11	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 325-332.	2.0	61
12	High-Fidelity Reprogrammed Human IPSCs Have a High Efficacy of DNA Repair and Resemble hESCs in Their MYC Transcriptional Signature. Stem Cells International, 2016, 2016, 1-14.	1.2	8
13	Persistent Multiyear Control of Relapsed Tâ€Cell Acute Lymphoblastic Leukemia With Successive Donor Lymphocyte Infusions: A Case Report. Pediatric Blood and Cancer, 2016, 63, 1279-1282.	0.8	5
14	Stable Reversion of Conventional Human Pluripotent Stem Cells to a Mouse ESC-like Naìve Ground State Erases Somatic Donor Epigenetic Memory and Significantly Improves Their Hemato-Vascular Differentiation Potency. Biology of Blood and Marrow Transplantation, 2016, 22, S426.	2.0	0
15	Nonmyeloablative Haploidentical BMT with Post-Transplant Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, S98.	2.0	O
16	Integrated Genomic Analysis of Diverse Induced Pluripotent Stem Cells from the Progenitor Cell Biology Consortium. Stem Cell Reports, 2016, 7, 110-125.	2.3	101
17	Tankyrase inhibition promotes a stable human na \tilde{A} -ve pluripotent state with improved functionality. Development (Cambridge), 2016, 143, 4368-4380.	1.2	64
18	Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. Biology of Blood and Marrow Transplantation, 2016, 22, 895-901.	2.0	64

#	Article	IF	CITATIONS
19	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen–Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 112-118.	2.0	37
20	Vascular Progenitors From Cord Blood–Derived Induced Pluripotent Stem Cells Possess Augmented Capacity for Regenerating Ischemic Retinal Vasculature. Circulation, 2014, 129, 359-372.	1.6	85
21	Cancer-like epigenetic derangements of human pluripotent stem cells and their impact on applications in regeneration and repair. Current Opinion in Genetics and Development, 2014, 28, 43-49.	1.5	7
22	Pivots of pluripotency: The roles of non-coding RNA in regulating embryonic and induced pluripotent stem cells. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2385-2394.	1.1	31
23	Growth Factor-Activated Stem Cell Circuits and Stromal Signals Cooperatively Accelerate Non-Integrated iPSC Reprogramming of Human Myeloid Progenitors. PLoS ONE, 2012, 7, e42838.	1.1	32
24	An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7921-7926.	3.3	36
25	Computational and Functional Analysis of Growth Hormone (GH)-Regulated Genes Identifies the Transcriptional Repressor B-Cell Lymphoma 6 (Bc16) as a Participant in GH-Regulated Transcription. Endocrinology, 2009, 150, 3645-3654.	1.4	27
26	SH2B1Î ² (SH2-BÎ ²) Enhances Expression of a Subset of Nerve Growth Factor-Regulated Genes Important for Neuronal Differentiation Including Genes Encoding Urokinase Plasminogen Activator Receptor and Matrix Metalloproteinase 3/10. Molecular Endocrinology, 2008, 22, 454-476.	3.7	33
27	Persistent Neonatal Thyrotoxicosis in a Neonate Secondary to a Rare Thyroid-Stimulating Hormone Receptor Activating Mutation:. Endocrine Practice, 2008, 14, 479-483.	1.1	28
28	Multiple mechanisms of growth hormone-regulated gene transcription. Molecular Genetics and Metabolism, 2007, 90, 126-133.	0.5	50
29	Profiles of Growth Hormone (GH)-regulated Genes Reveal Time-dependent Responses and Identify a Mechanism for Regulation of Activating Transcription Factor 3 By GH. Journal of Biological Chemistry, 2006, 281, 4132-4141.	1.6	40
30	Endogenous CCAAT/Enhancer Binding Protein \hat{I}^2 and p300 Are Both Regulated by Growth Hormone to Mediate Transcriptional Activation. Molecular Endocrinology, 2005, 19, 2175-2186.	3.7	38
31	Molecular mechanisms of age-related regulation of genes. International Congress Series, 2004, 1262, 562-565.	0.2	1
32	Growth Hormone Signal Transduction. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 771-86.	0.4	79
33	Age-related regulation of genes: slow homeostatic changes and age-dimension technology. Physica A: Statistical Mechanics and Its Applications, 2002, 315, 105-113.	1.2	0